What Gelofusine Treats: Main Uses and Benefits

Gelofusine is commonly used in situations involving certain distressing symptoms related to acute hypovolaemia and shock. This means it may be part of symptomatic management across conditions presenting with acute episodes of fluid deficit.

The medication is applied in addressing the symptoms related to systemic imbalance, specifically low blood pressure (hypotension), when caused by fluid deficits. It assists in re-establishing adequate blood pressure and may assist with maintaining sufficient blood flow to vital organs.

The applications include supporting patients during severe fluid loss from trauma, extensive burns, or haemorrhage, as well as being utilized proactively in the surgical setting and for the prevention of hypotension during regional anaesthesia. It helps maintain a sense of stability, supporting a stable physiological state during high-risk clinical procedures.

---

Quick Fact: Support for Volume-Related Symptoms

This volume substitute supports the patient during difficult episodes by easing distress related to sudden drops in circulation, contributing to restoring haemodynamic stability during phases of increased physiological stress.

The use of Gelofusine is strictly defined by regulatory documents, which establish absolute prohibitions and conditional restrictions based on patient characteristics and pre-existing conditions.

Category	Official Regulatory Statement
Contraindicated Populations	Prohibited for patients with hypersensitivity to gelatin or the excipients; hypersensitivity to alpha-Gal (e.g., red meat allergy); pre-existing hypervolaemia or hyperhydration; and acute congestive cardiac failure.
Condition-Specific Restrictions	Use requires special caution in patients with severe renal impairment (oligo- or anuria), major blood coagulation disorders, severe hypernatraemia or hyperchloraemia, and those at high risk of circulatory overload (e.g., pulmonary oedema).
Age-Related Eligibility	Paediatric Population: Use is not recommended due to insufficient clinical experience. Administration is limited to cases where expected benefits clearly outweigh potential risks. Elderly Patients: Caution is advised due to increased susceptibility to disorders like cardiac or renal insufficiency.
Pregnancy/Lactation Status	Pregnancy: Use should generally be avoided but is restricted to imperative emergency situations where the benefit is considered critical. Lactation: Insufficient information exists on excretion into breast milk.

Connection to the overall eligibility profile: Regulatory guidance defines eligibility primarily by the patient's capacity to handle the fluid load and the risk of allergic reaction. Non-eligibility is established when the volume expansion effect or the potential for severe allergy poses an unacceptable risk.

Interactions with other medicines and products

The use of Gelofusine solution requires caution due to two primary areas of interaction: specific medicinal products and interference with laboratory tests.

Pharmacodynamic Interactions

Concomitant administration of Gelofusine with medicines that can cause sodium retention, such as corticosteroids and non-steroidal anti-inflammatory agents (NSAIDs), should be done with caution. Since Gelofusine contains sodium, combining it with these agents may increase the risk of oedema (swelling due to fluid accumulation).

Effects on Blood Coagulation

Administration of relatively large volumes of Gelofusine can result in a dilutional effect on blood components. This dilution may affect the body’s natural coagulation process, potentially causing an increase in the Prothrombin time (PT) and a prolongation of the activated partial thromboplastin time (aPTT).

Interference with Laboratory Tests

Gelofusine may interfere with certain clinical-chemical tests, leading to falsely high values. Specifically, this effect has been documented for the erythrocyte sedimentation rate, the specific gravity of urine, and various unspecific protein assays (e.g., the Biuret method). To ensure accurate results, healthcare providers are generally advised to collect blood samples for laboratory tests, such as blood group or irregular antibody screening, before the infusion of Gelofusine begins.

Gelofusine is a colloidal plasma volume substitute that functions based on the physicochemical properties of its primary component, succinylated gelatin.

Colloidal Osmotic Pressure

Upon intravenous infusion, the succinylated gelatin molecules remain predominantly within the intravascular compartment due to their large molecular size. These molecules interact with the surrounding fluid by exerting a significant colloid-osmotic pressure (COP). The COP acts as the key interaction type, generating an osmotic gradient that draws water and electrolytes from the interstitial space (extravascular tissue fluid) into the capillaries.

Volume Expansion and Systemic Consequence

This influx of fluid initiates a mechanistic cascade resulting in a rapid, measurable increase in the circulating plasma volume. This volume expansion is proportional to the amount infused and sustains itself until the gelatin is metabolized. The resulting system-level physiological consequence is an increase in venous return to the heart, which directly modulates cardiac output. This process facilitates the restoration of systemic circulation and tissue perfusion.

How to use Gelofusine

Gelofusine is administered exclusively as a solution for infusion directly into the vein (intravenous use). The administration protocol is highly dynamic, meaning the required volume and speed of infusion are individually determined by the patient’s circulatory fluid deficit and constant medical monitoring, rather than a fixed schedule.

---

Administration Protocols and Dosing Constraints

Feature	Official Usage Principle
Route & Form	Intravenous use; ready-to-use 4% succinylated gelatin solution.
Initial Administration	The first 20 to 30 mL of the infusion must be administered slowly under close medical observation.
Dosing Range	The initial volume averages 500 to 1000 mL. The total maximum daily dose is functionally restricted by the need to prevent excessive haemodilution (blood dilution), necessitating monitoring to ensure haematocrit remains greater than or equal to 25% (or 30% in high-risk patients).
Rapid Infusion	In vital emergencies, 500 mL may be infused rapidly (e.g., over 5 to 10 minutes). If administered via pressure infusion, the solution should be warmed to a maximum of 37°C, and all air must be removed from the container and set.
Compatibility	The product is compatible with and can be administered through the same giving set as blood or packed red cells.

---

Population-Specific Use

Administration in pediatric patients is based on a careful assessment of risk versus benefit due to limited data, and the dose must be very carefully adjusted to meet individual requirements. Caution and dose adjustment are also mandated for older adults and patients with renal impairment to mitigate the risk of circulatory overload. The solution is used for acute volume deficits and is not intended for continuous daily therapy outside of acute management.

Gelofusine: Recent Clinical Evidence

The following is a summary of research investigating the properties and use of succinylated gelatin solution (Gelofusine) as a plasma volume substitute. This information describes what studies have explored and is not intended as medical advice or a statement on individual treatment suitability.

---

Efficacy and Volume Expansion

• Comparison to Crystalloids: Studies have shown that a smaller volume of colloid solution (such as Gelofusine) was associated with an equivalent expansion of blood volume when compared to a larger volume of crystalloid (salt) solutions. Colloids may also be associated with less fluid expansion in the interstitial tissue space (edema).
• Pharmacokinetics: The maximum volume expansion effect observed after infusion may be maintained for several hours before the volume effect is gradually lost, a duration typically longer than that seen with crystalloids, but shorter than human serum albumin.

---

Safety and Renal Function Investigations

• Renal Function: Research has investigated the effects of Gelofusine on the kidneys, with some studies focusing on whether the solution contributes to an increased urinary excretion of proteins, particularly low-molecular-weight proteins. This effect is thought to be due to competitive inhibition of tubular reabsorption.
• Acute Kidney Injury (AKI): In critically ill trauma patients, retrospective studies exploring high-dose Gelofusine use found no significant association between the solution and the initiation of renal replacement therapy (RRT) or the development of high-grade kidney injury.
• Hemostasis: The administration of gelatin-based plasma expanders has been shown to be associated with an impairment of primary hemostasis and thrombin generation in some human subjects.

Common questions about Gelofusine (FAQ)

Q: How quickly does Gelofusine start working?

A: Gelofusine is classified as a rapid volume substitute. Official studies and product information indicate that the fluid volume-expanding effect in the bloodstream is measurable and near-immediate after the infusion begins. The product's function is centered on the rapid restoration of lost circulatory fluid volume.

Q: How long does the effect of Gelofusine last in the body?

A: According to the official product information, the volume-expanding effect of Gelofusine in the circulation is generally described as lasting for approximately 3 to 4 hours before the substance is gradually cleared from the body.

Q: Does Gelofusine interact with common blood pressure medications?

A: Regulatory documents advise caution when Gelofusine is administered alongside other medicines that can cause the body to retain sodium, such as certain corticosteroids or non-steroidal anti-inflammatory agents (NSAIDs). Since Gelofusine itself contains sodium, this combination is noted to potentially increase the risk of swelling (oedema).

Q: Will Gelofusine affect my blood clotting or INR levels?

A: The administration of large volumes of Gelofusine can have a dilutional effect on blood components. Official safety documentation notes that this dilution may affect the body’s natural coagulation process, potentially prolonging test results such as the Prothrombin time (PT) and activated partial thromboplastin time (aPTT).

Q: Is it normal to feel dizzy or lightheaded after treatment?

A: Dizziness is documented in the safety profile of Gelofusine as a possible adverse reaction. It is listed as a potential symptom of a severe allergic reaction, which is a rare event, or as a symptom of decreased oxygen in the blood, which has an unknown frequency.

Q: Is Gelofusine given to children or only adults?

A: Official documents state that the safety and effectiveness of Gelofusine in the paediatric population have not been fully established due to limited clinical experience. Its use in children is generally not recommended and is limited to cases where the expected benefits clearly outweigh the potential risks, based on medical assessment.

Q: Can Gelofusine be given with other IV fluids at the same time?

A: Official product information explicitly notes that Gelofusine is compatible with and can be administered through the same giving set as blood or packed red cells. For any other types of solutions or medicines, the compatibility is required to be assessed by a healthcare professional.

Q: Can Gelofusine affect lab test results?

A: Yes, Gelofusine may interfere with certain clinical-chemical tests, which could lead to falsely high values. This effect is specifically documented for tests such as the erythrocyte sedimentation rate, the specific gravity of urine, and some unspecific protein assays.

Q: Is Gelofusine the same as saline (salt water drip)?

A: No, they are different types of fluids. Gelofusine is classified as a colloid solution, meaning it contains large molecules (succinylated gelatin) that are designed to remain in the blood vessels for a sustained period to replace lost volume. Saline (a salt water drip) is classified as a crystalloid, containing smaller molecules that leave the bloodstream more quickly.

Q: What is the difference between Gelofusine and other fluid replacements?

A: The key difference is its classification as a colloid solution. Colloids contain larger molecules that are effective at maintaining a sustained volume inside the blood vessels. Other common fluid replacements are often crystalloid solutions (like saline), which replace volume but are not retained in the blood vessels for as long.

Q: Are there any long-term side effects from getting Gelofusine?

A: Gelofusine is formally authorized and defined for use in the short-term, acute management of fluid loss, and it is not intended for continuous daily therapy. Because of this acute use context, the official safety documentation focuses on adverse reactions that may occur during or shortly after administration.

Q: Does Gelofusine contain any animal products?

A: The active ingredient in Gelofusine is succinylated gelatin, which is a derived compound produced by chemically modifying natural protein sourced from bovine collagen (cows). Official documents also note a specific contraindication for patients with a known allergy to red meat and offal.

Q: Is Gelofusine an electrolyte solution?

A: Gelofusine is primarily classified as a colloidal plasma volume substitute. However, it is a combination product, and its official composition confirms that it contains key electrolytes, specifically sodium chloride, which are dissolved along with the active gelatin agent.

Q: What is the main ingredient in Gelofusine that makes it work?

A: The main active substance is succinylated gelatin, which is also referred to as modified fluid gelatin. This substance is responsible for exerting the colloid-osmotic pressure (oncotic pressure) needed to draw fluid into the vessels and expand the blood volume.

Q: Is there a maximum amount of Gelofusine a person can receive?

A: The official documents state that the total maximum daily dose is not a fixed volume but is restricted by the need to prevent excessive dilution of the blood (haemodilution). The volume given is monitored to ensure the patient's haematocrit remains above a specified minimum level.

Q: Why is Gelofusine sometimes used for severe burns?

A: Gelofusine is listed in regulatory documentation as indicated for use as a plasma volume substitute in the initial management of hypovolaemic shock. This type of shock, which involves severe loss of circulating fluid volume, can be due to causes such as major trauma, surgery, or severe burns.

Q: What kind of research exists comparing Gelofusine to crystalloid solutions?

A: Research has investigated the efficacy of Gelofusine compared to crystalloid (salt) solutions, specifically focusing on the difference in the volume needed to achieve an equivalent expansion of the circulating blood volume. Research has noted that a smaller volume of colloid solution (Gelofusine) has been associated with an equivalent volume expansion compared to a larger volume of crystalloid solution.

Q: Are headaches a known side effect of Gelofusine?

A: Headache is documented as a potential symptom that can occur in the event of circulatory overload due to an overdose or if the infusion is administered too rapidly. This is documented as a symptom linked to circulatory overload and rapid infusion, rather than a generally listed adverse reaction.

Q: Does Gelofusine ever cause changes in urine output?

A: Yes, when used to treat hypovolaemia, the actions of Gelofusine are documented to include an increase in urinary output. A lack of improvement in urine output after the initial dose is noted in regulatory documents as a key clinical consideration for the medical team.

Q: Are there any religious or dietary concerns regarding the ingredients in Gelofusine?

A: The product is derived from bovine collagen (cows). Official documents note a specific medical contraindication for patients with a known allergy to red meat and offal, which is linked to a potential cross-reaction with the alpha-Gal allergen.

How to Store and Dispose of Gelofusine?

Gelofusine must be stored strictly according to the regulatory instructions to maintain its integrity and effectiveness. Official labeling mandates that the solution be stored below 25 C. It is explicitly required that you do not freeze or refrigerate the container.

Stability and Handling

The product is for single-use only and must be administered immediately after opening the container. Before use, the container should be checked, and the product must not be used if the solution is cloudy, discolored, or the container is leaking. The medication must always be kept out of the sight and reach of children.

Disposal Rules

Do not dispose of unused or expired Gelofusine via household waste or wastewater. Any partially used or unused solution must be properly discarded. Disposal must always follow the local requirements for pharmaceutical waste.